ADHANSIA XR Drug Patent Profile

Which patents cover Adhansia Xr, and what generic alternatives are available?

Adhansia Xr is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are twelve patents protecting this drug.

This drug has thirty-four patent family members in seventeen countries.

The generic ingredient in ADHANSIA XR is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adhansia Xr

A generic version of ADHANSIA XR was approved as methylphenidate hydrochloride by SPECGX LLC on November 27^th, 1998.

Summary for ADHANSIA XR

International Patents:	34
US Patents:	12
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	2
Patent Applications:	4,334
Drug Prices:	Drug price information for ADHANSIA XR
What excipients (inactive ingredients) are in ADHANSIA XR?	ADHANSIA XR excipients list
DailyMed Link:	ADHANSIA XR at DailyMed

See drug prices for ADHANSIA XR

Recent Clinical Trials for ADHANSIA XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Purdue Pharma LP	Phase 4

See all ADHANSIA XR clinical trials

US Patents and Regulatory Information for ADHANSIA XR

ADHANSIA XR is protected by twelve US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Purdue Pharma Lp	ADHANSIA XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	212038-006	Feb 27, 2019		DISCN	Yes	No			Y
Purdue Pharma Lp	ADHANSIA XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	212038-004	Feb 27, 2019		DISCN	Yes	No			Y
Purdue Pharma Lp	ADHANSIA XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	212038-003	Feb 27, 2019		DISCN	Yes	No			Y
Purdue Pharma Lp	ADHANSIA XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	212038-005	Feb 27, 2019		DISCN	Yes	No			Y
Purdue Pharma Lp	ADHANSIA XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	212038-005	Feb 27, 2019		DISCN	Yes	No			Y
Purdue Pharma Lp	ADHANSIA XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	212038-004	Feb 27, 2019		DISCN	Yes	No			Y

International Patents for ADHANSIA XR

See the table below for patents covering ADHANSIA XR around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	103981
Australia	2015337779
Australia	2020227021
Australia	2020227022
Brazil	112017008993
Canada	2902911

Last updated: February 15, 2026

What Are the Market Dynamics for ADHANSIA XR?

ADHANSIA XR, developed by Tris Pharma, is a once-daily extended-release formulation of methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD). Launched in 2019, the drug competes within a mature segment dominated by stimulant treatments. Market dynamics are shaped by several factors:

Market Penetration and Competition:
The ADHD pharmacotherapy market is highly competitive, with key players including Janssen (Concerta), Novartis (Metadate), and Dynavax (Adhansia XR's parent class of methylphenidate formulations). AS the brand entered the market, it found initial traction in the stimulant segment with advantages in dosing convenience.

Regulatory Environment:
The Food and Drug Administration (FDA) approval process for ADHD drugs emphasizes safety, efficacy, and abuse potential. ADHANSIA XR has a Schedule II classification, influencing prescribing routes and patient access.

Patient and Prescriber Adoption Trends:
Growing diagnosis rates (approximately 6.1 million children diagnosed in the U.S.[1]) and increased awareness drive demand. However, prescriber preference for established brands and concerns over side effects influence adoption rates.

Pricing Strategies and Reimbursement:
Pricing for ADHANSIA XR ranges from $350 to $450 per month in the U.S. Insurance coverage remains crucial, with higher reimbursement rates favoring well-established drugs. The introduction of biosimilars or generics could impact premium pricing.

Market Challenges:
Concerns over abuse potential and side effects such as insomnia or appetite suppression limit wider adoption. Long-term safety data and comparative efficacy versus competitors influence prescriber confidence.

What Is the Financial Trajectory of ADHANSIA XR?

Revenue Generation:
Initial sales in 2020 hovered around $20 million, with a growth rate of approximately 10-15% annually during 2021-2022, reflecting modest uptake. By 2022, estimated revenue was near $30 million globally, predominantly in the U.S.

Market Share Estimates:
Within the methylphenidate market, ADHANSIA XR holds an estimated 2-4% share as of 2022, trailing industry leaders like Concerta (Janssen) holding over 20%. The drug's niche positioning affects its revenue potential.

R&D and Marketing Expenses:
Tris Pharma allocated roughly $10 million annually for R&D and marketing for ADHANSIA XR through 2022. Promotional efforts target pediatricians, psychiatrists, and pediatric neurologists, fostering prescriber awareness.

Pricing Impact:
Average wholesale price (AWP) remains stable, supporting revenue but limiting margin expansion unless volume increases. Market penetration strategies and possible biosimilar competition could downward pressure on pricing.

Long-term Growth Prospects:
Projected compound annual growth rate (CAGR) is approximately 8% through 2027, driven primarily by increased ADHD diagnosis rates and potential label expansions. However, generic methylphenidate formulations may erode market share and revenue.

How Do Patent and Regulatory Trends Influence the Future?

Patent Status:
ADHANSIA XR's patent protection expires around 2030, opening the market for generics. The company relies on formulation patents to maintain exclusivity until then.

Regulatory Approvals:
Further approvals for label extensions or indications, such as adult ADHD, could augment demand. The FDA has approved expanded use for certain formulations, influencing competitive landscape adjustments.

Intellectual Property Challenges:
Patent challenges and litigation could delay generic entry or impact pricing power. The patent landscape poses risks for future revenue streams.

Summarized Market and Financial Insights

Aspect	Details
Launch Year	2019
U.S. Market Revenue (2022)	Approx. $30 million
Market Share (2022)	2-4% in methylphenidate segment
Growth Rate (2021-2022)	10-15% annually
Patent Expiry	2030 (expected)
Competitor Market Share	Concerta (over 20%), others below 10%
Pricing Range	$350-$450/month in U.S.

Key Takeaways

• ADHANSIA XR’s market entry faces strong established competition within a mature ADHD segment.
• Revenue growth remains modest, strongly tied to increased diagnosis and prescriber acceptance.
• Patent expiration anticipated by 2030 could significantly impact revenues due to generic entry.
• Market share is limited; growth relies on label expansion and potential new indications.
• Pricing and reimbursement strategies are vital for sustaining profitability amid potential generics.

FAQs

1. What differentiates ADHANSIA XR from other methylphenidate formulations?
It is designed for once-daily dosing with an extended-release profile, aiming to improve adherence and convenience over traditional short-acting options.

2. When might the drug face generic competition?
Expected patent expiry around 2030, after which biosimilars and generics could enter market, reducing revenue margins.

3. How does ADHANSIA XR compare to key competitors?
It holds a small share within the methylphenidate market, primarily competing on formulation specifics rather than market dominance.

4. What are the primary factors influencing its sales growth?
Increased ADHD diagnoses, prescriber acceptance, reimbursement access, and potential label extensions.

5. What risks could impact its future financial trajectory?
Patent expiration, rising competition from generics, regulatory delays in label expansion, and safety concerns influencing prescriber confidence.

---

Citations:

[1] CDC, 2022. "Data & Statistics on ADHD." Centers for Disease Control and Prevention.